Clinical Trials Browser

Phase 3 × INDUSTRY × Carcinoma, Transitional Cell × Clear all

NCT03967977 2026-04-17

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

Phase 3 Active not recruiting

Carcinoma, Transitional Cell

NCT07218380 2026-04-17

FORAGER-2

Phase 3 Recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT07526792 2026-04-13

SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Phase 3 Not yet recruiting

Carcinoma, Transitional Cell

NCT05911295 2026-04-07

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Phase 3 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03815643 2026-03-31

Avelumab Program Rollover Study

Phase 3 Active not recruiting

GenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Ovarian Neoplasms

NCT07393542 2026-03-03

A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma

Phase 3 Recruiting

Carcinoma, Transitional Cell

NCT03898180 2026-02-05

LEAP-011

Phase 3 Completed

505 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT06774131 2026-01-16

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

Phase 3 Recruiting

Carcinoma, Transitional Cell

NCT06331299 2026-01-15

UTOPIA

Phase 3 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06111235 2026-01-12

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Phase 3 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT06857175 2025-09-12

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma

Phase 3 Recruiting

Carcinoma, Transitional Cell

NCT03374488 2025-08-22

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

Phase 3 Completed

84 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT02807636 2025-02-24

IMvigor130

Phase 3 Completed

1,213 enrolled 35 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05243550 2024-11-04

ENVISION

Phase 3 Active not recruiting

240 enrolled 20 charts 3 FDA

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05136898 2024-09-19

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

Phase 3 Completed

8 enrolled 18 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06592326 2024-09-19

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

Phase 3 Recruiting

Carcinoma, Transitional Cell

NCT04688931 2024-06-06

ATLAS

Phase 3 Terminated

282 enrolled 29 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02603432 2024-03-27

JAVELIN Bladder 100

Phase 3 Completed

700 enrolled 35 charts 3 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT05302284 2023-12-18

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

Phase 3 Recruiting

Carcinoma, Transitional Cell

NCT02426125 2023-08-21

RANGE

Phase 3 Completed

530 enrolled 22 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urethral Neoplasms

NCT02450331 2023-06-18

IMvigor010

Phase 3 Terminated

809 enrolled 19 charts

Carcinoma, Transitional Cell

NCT02793128 2020-12-22

Olympus

Phase 3 Completed

71 enrolled 16 charts 3 FDA

Carcinoma, Carcinoma, Transitional Cell

NCT04006691 2020-05-07

Retreatment

Phase 3 Withdrawn

Carcinoma, Carcinoma, Transitional Cell

NCT02982395 2019-08-30

Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC

Phase 3 Terminated

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01310803 2017-10-05

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Phase 3 Terminated

1 enrolled 5 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT01200992 2017-08-24

EMBARC-RF

Phase 3 Terminated

84 enrolled 7 charts

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Mycobacterium Infections, Neoplasm Recurrence, Local, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT00315237 2010-01-07

Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract

Phase 3 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell